Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
| | |||
Ablynx NV* |
Genencor International Inc. (GCOR) |
Ablynx will use its Nanobody platform to discover and develop drug candidates against Genencor tumor targets |
Ablynx will receive research funding and license fees in addition to potential milestone payments and royalties on resulting sales (9/20) |
ActiveSight* |
Lexicon Genetics Inc. (LEXG) |
Deal for crystallography of certain Lexicon compounds with a human drug target protein |
ActiveSight will provide services to Lexicon subsidiary Lexicon Pharmaceuticals; terms were not disclosed (11/8) |
Advanced Cell |
Lifeline Cell Technology LLC* |
Lifeline got rights to use certain embryonic stem cell technology to produce retinal cells for therapeutic research |
Terms of the exclusive license deal were not disclosed (10/11) |
Affibody AB* |
Astra Tech AB* (Sweden) |
License and research deal for the development of devices for safe blood management |
Affibody will develop molecules to remove harmful proteins from blood, and will get research funding for three years, as well as potential milestones and royalties (9/16)# |
Affitech A/S* |
Peregrine Pharmaceuticals Inc. (PPHM) |
They expanded antibody collaboration to include the production of fully human monoclonal antibodies against up to six additional targets |
They had been working on three targets in cancer and viral disease; Affitech is eligible for research fees, milestone payments and royalties on any sales (11/8) |
Affymetrix |
Genospectra Inc.* |
Genospectra licensed patents related to beads and gene-expression analysis |
The nonexclusive license covers research use only; terms of the deal were not disclosed (11/10) |
Amgen Inc. |
Nuvelo Inc. (NUVO) |
Nuvelo gained worldwide rights to the thrombolytic agent alfimeprase, for which the companies entered a collaboration in 2002 |
Amgen opted for a license arrangement on the Phase II product rather than leading development; Amgen is eligible for milestone and royalty payments (11/1) |
Apath LLC* |
Nucleonics Inc.* |
Nucleonics licensed technology related to the 3' nontranslated region of the hepatitis C viral genome |
Nucleonics will use the region as a target for development of an expressed RNAi therapeutic; terms of the nonexclusive license were not disclosed (11/17) |
Aphton Corp. |
XOMA Ltd. (XOMA) |
Deal to apply XOMA's engineering technology to monoclonal antibodies developed by Aphton, for use against gastrin-sensitive cancers |
Aphton and XOMA will shares costs and any profits on a 70-30 basis, respectively; XOMA has manufacturing rights, and Aphton has commercialization rights outside the U.S. (9/23) |
ASAT AG* |
Biofrontera AG* (Germany) |
Biofrontera acquired a Phase II product for cancerous and noncancerous skin lesions, and gynecological indications |
Terms were not disclosed; the product is a nanocolloid formulation of aminolevulinic acid, suited for photodynamic therapy (10/7) |
Benitec Ltd. |
Artemis Pharmaceuticals GmbH* (Germany) |
Artemis got a nonexclusive license to use ddRNAi technology for transgenic mouse and rat model development |
Benitec gets an up-front license fee and royalties on sales (10/28) |
Benitec Ltd. |
Panomics Inc.* |
Panomics got nonexclusive rights to make and sell DNA-directed RNAi-based products |
Terms of the deal were not disclosed; Panomics focuses on the reagent market (10/20) |
Benitec Ltd. |
Revivicor Inc.* |
Revivicor got nonexclusive rights to use ddRNAi technology in its xenotransplantation programs |
Benitec gets an up-front and annual payments, and would get a milestone payment upon FDA approval and royalties on sales (10/8) |
BioCrystal |
Crystaplex Corp.* |
Cross-licensing deal covering fluorescent biomolecular assaying platforms |
They also will collaborate to develop products using each company's technology; terms were not disclosed (11/1) |
BioFocus plc |
Biovitrum AB* (Sweden) |
Biovitrum gained rights to drug candidates for obesity, generated from their GPCR lead-generation joint venture |
BioFocus gets an undisclosed up-front payment along with potential milestones and royalties; the program is at the end of the lead-generation stage (9/22) |
Bionomics Ltd. |
Genetic Technologies Ltd. (Australia; ASX:GTG) |
Alliance to commercialize new genetic tests for epilepsy |
GTG got worldwide testing and marketing rights to Bionomics' epilepsy tests; Bionomics got a license to GTG noncoding patents; Bionomics gets a signing fee and potential sales royalties and milestones; GTG gets a license fee (11/7) |
Bio-Rad |
Calypte Biomedical Corp. (AMEX:HIV) |
Calypte got a nonexclusive license to patents relating to HIV-2 |
The deal will allow Calypte to broaden its diagnostic testing; terms were not disclosed (10/4) |
BioTie |
Somaxon Pharmaceuticals Inc.* |
Somaxon exercised its option to exclusively license North American rights to nalmefene for treating impulse-control disorders |
Terms of the July 2004 option deal called for BioTie to get a $3M license fee and up to $10M in development milestones, as well as royalties on any sales of the selective opi- oid receptor antagonist (11/12) |
Cambridge |
Prestwick Pharmaceuticals Inc.* |
Prestwick acquired rights to tetrabenazine in Canada under the brand name Nitoman |
Tetrabenazine is a dopamine depletor approved in Canada for treating hyperkinetic movement disorders; Prestwick is developing the product in the U.S. (9/20) |
Celera |
Genentech Inc. (NYSE:DNA) |
Genentech may further develop products against therapeutic targets chosen by Celera |
Celera is entitled to milestone payments and royalties on any sales; Celera Diagnostics retains certain diagnostic rights related to the targets (9/28) |
Cengent |
Dynamis Therapeutics Inc.* |
Cengent will screen drug candidates against diabetic-related kidney and heart disease, blindness and neuropathy |
The Dynamis drug target is an enzyme that causes the formation of 3-deoxyglucosone; Cengent will get up-front and potential milestone payments (11/15) |
Chromos |
Ex Vivo Technologies Inc.* |
Nonexclusive deal under which Ex Vivo will use Chromos' ACE System for research purposes |
Ex Vivo will use the system to genetically modify adult-derived stem cells in exchange for up-front and annual maintenance payments (10/7) |
Cyclacel Group |
Corgentech Inc. (CGTK) |
Corgentech licensed an endonuclear delivery system for use with its transcription factor decoy technology |
Cyclacel gets an up-front payment and potential milestone and royalty payments for licensing its Penetratin technology (9/27) |
Cyntellect |
Protein Design Labs Inc. (PDLI) |
PDL gained access to Cyntellect's Cell Xpress service |
The technology is used in monoclonal antibody and protein production; terms of the the deal were not disclosed (10/26) |
Dekk-Tec |
Ziopharm Inc.* |
Ziopharm secured a worldwide license to a form of isophosphoramide mustard |
The oncology product, ZIO-201, is in Phase I trials; terms of the deal were not disclosed (11/10) |
Domantis Ltd.* |
Argenta Discovery Ltd.* (UK) |
Deal to co-develop fully human domain antibodies for COPD and other respiratory diseases |
The deal will combine Domantis' antibodies with Argenta's expertise in chronic obstructive pulmonary disease; revenues would be shared (10/26) |
Dyax Corp. |
Biogen Idec Inc. (BIIB) |
Biogen Idec gets access to Dyax's fully human antibody libraries against up to 30 protein targets per year |
Dyax is getting research support for a minimum of three years; Biogen Idec gets rights to resulting candidates in exchange for milestone and royalty payments (11/10) |
Dyax Corp. |
Inhibitex Inc. (INHX) |
Deal to discover and develop products for preventing or treating enterococcal infections |
They will use Dyax's phage display technology to discover antibodies against Inhibitex's MSCRAMM proteins; costs and profits will be shared equally (10/26) |
EntreMed Inc. |
Affymax Inc.* |
Collaboration to synthesize and develop peptides that mimic certain fragments of tissue factor pathway inhibitor |
They will combine expertise in peptide design and drug development to identify candidates for treating cancer; terms were not disclosed (10/26) |
Epigenomics |
Biogen Idec Inc. (BIIB) |
Epigenomics will use its DNA methylation technology to examine biomarkers that might predict responsiveness to a Biogen Idec cancer drug |
Epigenomics will receive R&D funding and has an opportunity to participate in the development of a potential pharmacodiagnostic product (10/7) |
Evogene Ltd.* |
Compugen Ltd. (Israel; CGEN) |
Evogene will evaluate the production of three Compugen therapeutic protein candidates |
Evogene will use its plant-based protein- production platform in the deal, terms of which were not disclosed (10/25) |
Evotec OAI AG |
Hydra Biosciences Inc.* |
Evotec will provide biology and screening services to identify active compounds against a Hydra ion channel target |
Terms of the deal were not disclosed (9/21) |
4SC AG* |
Mutabilis SA* (France) |
4SC will use its high-throughput screening technology to identify compounds that bind to a specific Mutabilis target |
4SC receives undisclosed research funding and will be eligible for milestone payments; the focus is on anti-infectives (9/21) |
Genaissance |
Pyxis Genomics Inc.* |
Genaissance will provide high-throughput genotyping services to Pyxis |
The services will be used to commercialize Pyxis' Profile-1 System; Genaissance will get fees for each test it performs (10/21) |
Genelabs |
Gilead Sciences Inc. (GILD) |
Genelabs will lead research and Gilead development in a collaboration to develop drugs for hepatitis C |
Genelabs gets $8M up front and research funding for three years, as well as up to $38M in milestone payments for each compound developed by Gilead, which gets worldwide rights and would pay royalties on any sales (9/30) |
Genetic |
Genzyme Corp. (GENZ) |
Genzyme got nonexclusive rights to a range of human genetic testing applications |
GTG gets a signing fee and an annual fee for the life of certain noncoding patents; the deal was expected to be the first step in a collaboration (10/11) |
Genetronics |
Vical Inc. (VICL) |
Vical exercised its option to use Genetronics' MedPulser DNA Delivery System |
Vical can use the system for a solid-tumor application and HIV in exchange for an upfront payment and potential milestones and royalties; Vical also got an option to other targets (10/26) |
Geron Corp. |
Revivicor Inc.* |
Revivicor got rights to use nuclear- transfer technology to produce animal organs and tissues for xenotransplantation, and to produce human proteins from the blood of animals for pharmaceutical uses |
In exchange for granting the two non- exclusive licenses, Geron received an equity interest in Revivicor and would get royalties on sales (11/16) |
GenPat77 |
MedImmune Inc. (MEDI) |
MedImmune got an exclusive license to GenPat77's TIRC7 program, involving a molecule implicated in immune regulation |
GenPat77 gets an up-front payment and funding for associated preclinical R&D; it also is eligible for milestone and royalty payments (9/30) |
Global |
Rheoscience A/S* (Denmark) |
Rheoscience will use Global's tangerine gene-expression profiling to study targets in metabolic diseases |
Terms of the deal were not disclosed (9/20) |
GTC |
Nexia Biotechnologies Inc. (Canada; TSE:NXB) |
Nexia gained a license to transgenic technology for use in its Protexia product |
Protexia is a recombinant form of butyryl-cholinesterase produced in the milk of transgenic goats; the deal includes access to GTC's beta casein promoter and an option to its filtration technology (9/23) |
Guilford |
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
Angiotech licensed patents covering use of biocompatible polymers for delivery of chemotherapeutic drugs |
Guilford will receive about $6M in the deal; Guilford previously had licensed the patents from MIT and Johns Hopkins University (9/17) |
ImmPheron Inc.* |
InNexus Biotechnology Inc. (Canada; VSE:ISX) |
InNexus is acquiring antibodies for treating coronary heart disease and chronic viral diseases |
ImmPheron gets $50,000 and 500,000 InNexus shares, which were valued at about $140,000; it also would get royalties of 3%, and 10% of any revenue from third-party licenses (9/20) |
ImmunoGen |
Biogen Idec Inc. (BIIB) |
Biogen Idec got rights to use Tumor-activated Prodrug technology with antibodies to an undisclosed tumor-cell target |
ImmunoGen gets $1M up front and up to $42M in milestones, as well as compensation for research and production, and royalties on any sales (10/6) |
Inhibox Ltd.* (UK) |
TopoTarget A/S* (Denmark) |
Inhibox will provide its virtual screening technology to TopoTarget for identifying lead cancer candidates |
Inhibox will attempt to identify an inhibitor of a TopoTarget enzyme; TopoTarget has an option to initiate further screens against other targets; terms were not disclosed (11/9) |
Inpharmatica |
Serono SA (Switzerland; NYSE:SRA) |
They expanded collaboration on developing secreted proteins identified by Inpharmatica's PharmaCarta technology |
They now will work on validating proteins discovered under the deal that started in 2001; Inpharmatica got $1.5M for granting Serono additional rights, and is eligible for milestone and royalty payments (11/16) |
InnoCore |
OctoPlus Technologies BV* (the Netherlands) |
Collaboration to develop and market an injectable drug delivery platform |
The platform is based on InnoCore's SynBiosys, a biodegradable polymeric system; terms of the deal were not disclosed (10/21) |
Inovio A/S* |
Shanghai H&G Biotechnology Co.* (China) |
Deal for preclinical evaluation of DNA vaccines against tuberculosis and a gene- based hCG-beta cancer vaccine |
Shanghai H&G is responsible for developing vaccines, which will incorporate Inovio's Elgen gene delivery system; terms were not disclosed (9/19) |
Lynx |
Solexa Ltd.* (UK) |
Lynx will get additional funding to accelerate development of a DNA-sequencing instrument |
The funding is in addition to a $2.5M loan Solexa provided when the companies announced their intention to merge (10/28) |
Nautilus |
Serono SA (Switzerland; NYSE:SRA) |
Serono licensed rights to a next- eneration human growth hormone, and got an option to license improved variants of the protein |
Nautilus gets an initial fee and milestone payments that could reach €19M if Serono develops a new version under its option; it also would get royalties; Serono's rights and option are exclusive (11/15) |
Neurome Inc.* |
ImClone Systems Inc. (IMCL) |
Neurome will apply quantitative neuropathology technology to preclinical molecules from ImClone |
The work will focus on targets in the central nervous system; terms were not disclosed (9/23) |
Newron |
Dynogen Pharmaceuticals Inc.* |
Dynogen gained rights to a number of preclinical ion channel modulators |
Dynogen will explore their potential in genitourinary and gastrointestinal disorders; terms of the exclusive, worldwide license were not disclosed (10/12) |
Norak |
Curis Inc. (CRIS) |
Deal to investigate the use of Norak's Transfluor technology with a class of receptors of interest to Curis |
Norak will develop cell lines expressing Curis' receptors; terms of the deal were not disclosed (10/20) |
NovaDel |
Hana Biosciences Inc. (OTCBB:HNAB) |
Deal to develop and market NovaDel's lingual spray version of the anti-emetic ondansetron |
Hana gained exclusive rights in the U.S. and Canada; Hana made an undisclosed equity investment in NovaDel, which gets equity in Hana as well as potential milestone payments and double-digit royalties (10/27) |
Odyssey |
Panbio Ltd. (Australia; ASX:PBO) |
Panbio licensed a system for detecting disease in humans and animals |
Odyssey gets an up-front fee and royalties on any sales (10/19) |
Oriel |
Undisclosed company |
Deal to develop a product for cystic fibrosis using Oriel's dry-powder inhalation technology |
Oriel said it could get "several million dollars“ in license fees and milestone payments, as well as royalties on any sales (9/28) |
OriGene |
MacroGenics Inc.* |
MacroGenics licensed rights to develop compounds against a cancer target identified by OriGene |
OriGene will be entitled to various option fees, milestones and royalty payments as compounds are developed and commercialized (10/19) |
Ortec |
Hapto Biotech Inc.* (Israel) |
Formed joint venture to further develop leads identified in their September 2002 collaboration |
They will use Hapto peptides with Ortec's collagen biomaterial in various indications; they plan to seek partners (10/11) |
OXIS International |
HaptoGuard Inc.* |
HaptoGuard got exclusive, worldwide rights to BXT-51072 and related compounds for cardiovascular indications |
OXIS gets $450,000 up front and up to $20.5M in milestones, as well as royalties on any sales of the antioxidant compounds (9/28) |
Paratek |
Serono SA (Switzerland; NYSE:SRA) |
Deal to discover and develop orally available tetracycline derivatives for treating multiple sclerosis |
Paratek gets up-front and research funding, a convertible loan, and potential milestone and royalty payments; the milestones could total $38M for the first product (10/27) |
Phares |
Inyx Inc. (OTC BB:IYXI) |
Inyx acquired a technology for developing inhalation therapies delivered in aerosol formats |
The technology uses a lipid-binding matrix for delivering incompatible or unstable drug substances; terms were not disclosed (9/21) |
Pharmacopeia Drug |
Biovitrum AB* (Sweden) |
Deal to identify and optimize small molecules for multiple metabolic disease targets |
Biovitrum will access Pharmacopeia's compound collection and discovery expertise in exchange for an up-front payment and potential milestones and royalties (10/26) |
Pharmacopeia |
Neurocrine |
Agreement to expand and extend their collaboration for drug discovery |
They will further optimize compounds del- ivered to Neurocrine; Pharmacopeia is entitled to milestone and royalty payments (10/25) |
Primogenix Inc.* |
Chemicon International Inc. (division of Serologicals Corp.; SERO) |
Chemicon acquired assets related to two mouse embryonic stem cell product lines |
Terms of the deal were not disclosed (11/3) |
ProBioGen AG* (Germany) |
Millennium Pharmaceuticals Inc. (MLNM) |
ProBioGen will develop cell lines for Millennium antibodies and manufacture preclinical trial materials |
ProBioGen will use its Position Mediated Expression Enhancement technology in the deal, terms of which were not disclosed (11/3) |
ProBioGen AG* (Germany) |
Chiron Corp. (CHIR) |
Deal to evaluate ProBioGen's vaccine cell lines for vaccine production |
Under the deal, involving Chiron Vaccines, each has option rights to enter a collaboration for further development; terms were not disclosed (10/4) |
Proteom Ltd.* |
14TM Ltd.* (UK) |
Partnership initially focused on the design of novel ligands to a range of GPCR targets |
They will exploit the synergy between their technologies in the deal, terms of which were not disclosed (10/28) |
Protherics |
Morvus Technology Ltd.* (UK) |
Morvus acquired the R&D function of the former Enact Pharma plc, which Protherics acquired in 2003 |
Protherics retains a five-year right of first refusal on certain products, and gets an equity stake of £150,000 in Morvus (9/22) |
Protherics |
NanoMor Biomedical Ltd.* (UK) |
NanoMor acquired certain patents that came with Enact Pharma plc, which Protherics acquired in 2003 |
Protherics would get a royalty on any resulting sales, and gets an equity stake of up to 2% in NanoMor (9/22) |
Rinat |
Genentech Inc. (NYSE:DNA) |
Genentech exercised its option to co-develop and sell RI 624, a humanized monoclonal antibody in Phase I trials |
Rinat gets a $20M up-front payment and an equity investment; they will share worldwide costs and profits related to the nerve growth factor for pain indications (11/9) |
Santhera |
Genzyme Corp. (GENZ) |
Genzyme got nonexclusive rights to a cellular screening system for discovery of therapies for muscle diseases |
Santhera gets a license fee; Genzyme has an option to an exclusive worldwide license to a subset of Santhera's small-molecule compounds for Duchenne's muscular dys- trophy and related diseases (10/7) |
SeqWright Inc.* |
VisiGen Biotechnologies Inc.* |
SeqWright will help validate Visigen's whole-genome sequencing technology |
SeqWright gets undisclosed cash and stock payments from VisiGen; further terms were not disclosed (11/9) |
Thiakis Ltd.* |
Nastech Pharmaceutical Co. Inc. (NSTK) |
Nastech acquired exclusive rights to patents for intranasal delivery of PYY, and the use of glucagon-like peptide-1 with PYY for metabolic conditions |
Thiakis got an equity investment, and is entitled to license fees, milestone payments and royalties on sales; Thiakis got the patents from Imperial College Innovations and Oregon Health & Science University (9/27) |
ThromboGenics Ltd* (Ireland) |
BioInvent International AB (Sweden; SSE:BINV) |
Collaboration to develop antibody-based drugs for cardiovascular indications, starting with ThromboGenics' anti-Factor VIII antibody |
They each will contribute technology to the effort, and will share costs and revenues equally; a 60-40 revenue split would be used for compounds identified before the collaboration (9/28) |
Tm Bioscience |
Genzyme Corp. (GENZ) |
Deal to develop, validate and implement an undisclosed custom product |
A product based on Tm's genetic testing technology was expected to yield initial sales in 1H:05; terms of the deal were not disclosed (11/9) |
Tripos Inc. |
Strida Pharma Inc.* (Canada) |
Tripos and NovaScreen will supply drug discovery support services to Strida |
The focus is a Strida cancer target, methyl |
XOMA Ltd. |
Zephyr |
Zephyr got exclusive worldwide rights to XOMA products related to bactericidal/permeability-increasing protein, including Neuprex |
XOMA gets up to $11M in license fees and milestone payments of up to $62M, as well as royalties on any sales; the deal does not include BPI-derived peptide products (11/10) |
XOMA Ltd. |
Triton BioSystems Inc.* |
Triton got rights to XOMA's ING-1 monoclonal antibody for use with its Targeted Nano-Therapeutics System |
The anticancer antibody has affinity to the Ep-CAM antigen; terms of the worldwide, exclusive license were not disclosed (10/4) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before Sept. 17 but was not included in the previous chart. | |||
Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; HEX = Helsinki Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | |||
To read more on related topics, click on one of the words below.